These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19918651)

  • 1. [Basal-like breast cancers: clinicopathological features and outcome].
    De Brot M; Soares FA; Stiepcich MM; Cúrcio VS; Gobbi H
    Rev Assoc Med Bras (1992); 2009; 55(5):529-34. PubMed ID: 19918651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
    Dabbs DJ; Chivukula M; Carter G; Bhargava R
    Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].
    Mainka P; Kahlert S; Kirchner T; Mayr D; Diebold J
    Pathologe; 2008 Nov; 29 Suppl 2():363-9. PubMed ID: 18807040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
    Paredes J; Lopes N; Milanezi F; Schmitt FC
    Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Morphological features of basal-like subtype invasive carcinoma of breast].
    Gao LX; Yang GZ; Ding HY; Li L
    Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
    Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers in triple-negative breast cancer.
    Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
    Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
    Bryan BB; Schnitt SJ; Collins LC
    Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-erbB-2 and the "triple-state" in early breast carcinomas.
    Sivridis E; Stamos C; Fiska A; Nikolettos N; Koukourakis MI; Giatromanolaki A
    Med Oncol; 2010 Sep; 27(3):578-84. PubMed ID: 19548127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
    Sasa M; Bando Y; Takahashi M; Hirose T; Nagao T
    J Surg Oncol; 2008 Jan; 97(1):30-4. PubMed ID: 17929254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
    Niwińska A; Olszewski W; Murawska M; Pogoda K
    J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.